TrialBlood advances2020
Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis.
Andrew Staron et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
22 papers cite it
this paperpooled ittrialcites it